Almost two-thirds of people newly diagnosed with multiple sclerosis (MS) in the United States, identified through a national database, were not prescribed disease-modifying therapies (DMTs) over an average of more than two years of follow-up, a real-world study of nearly 5,700 patients found. Current guidelines “recommend early treatment with…

Higher Risk of Vascular Disease Among MS Patients in the UK, Population-based Study Reveals You’d think that people with multiple sclerosis (MS) would be likely to have vascular disease due to the sedentary lifestyles many of us lead. But this large, lengthy study that looks at the records of…

Glatopa, a generic form of Copaxone, is as effective as the brand-name medication in terms of disease outcomes and has similar healthcare-related costs in real-world use in patients with relapsing multiple sclerosis (MS), a new U.S. study suggests. Data also suggest a trend toward lower relapse rates with Glatopa…

People with relapsing multiple sclerosis (MS) have a better prognosis and a slower progression to disability since the introduction of disease-modifying treatments (DMTs) some 20 years ago, according to a retrospective study. The study, “Outcomes in a Modern Cohort of Treated Multiple Sclerosis Patients Followed from Diagnosis Up…

The question of how quickly to start a disease-modifying therapy (DMT) after a multiple sclerosis (MS) diagnosis is one that I frequently see when I browse online. It goes hand in hand with questions about which DMT is best to start with. There are many things to consider when…

Pendopharm’s Glatect (glatiramer acetate injection), a lower cost alternative to Teva’s Copaxone, has been added to the public health plans of five Canadian provinces for patients with…

The U.S. Food and Drug Administration has approved a new dose of Sandoz’s multiple sclerosis therapy Glatopa (glatiramer acetate injection) that is twice as large as the currently authorized one. Regulators’ approval of the 40 mg/mL applies to people with relapsing forms of MS. A mg/mL designation refers to the concentration of…

Insurance companies want people to use generics, rather than the more expensive brand-name drugs, right? Maybe not. Because, at least in some cases, they’re doing just the opposite. Some patients are being forced to use brand-name drugs even when those drugs have generic equivalents. Not surprisingly, that means…

In a recent study entitled “Equivalent Gene Expression Profiles between Glatopa™ and Copaxone®,” authors determined potential differences in treatment responses by investigating the gene expression profile of two approved treatments for relapsing forms of multiple sclerosis – Copaxone and Glatopa. Both of these MS therapies are glatiramer…